Drug Patents owned by Janssen Pharms

1. Drug name - INVEGA HAFYERA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10143693 JANSSEN PHARMS Dosing regimen for missed doses for long-acting injectable paliperidone esters Apr, 2036

(13 years from now)

Drugs and Companies using PALIPERIDONE PALMITATE ingredient

Treatment: Reinitiation of schizophrenia treatment following a missed dose more than 9 months ago; reinitiation of schizophrenia treatment following a missed dose 4-9 months ago

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage
Strength Dosage Availability
1.092GM/3.5ML (312MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
1.560GM/5ML (312MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
273MG/0.875ML (273MG/0.875ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
410MG/1.315ML (311.79MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
546MG/1.75ML (312MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
819MG/2.625ML (312MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription

2. Drug name - INVEGA SUSTENNA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9439906 JANSSEN PHARMS Dosing regimen associated with long acting injectable paliperidone esters Jan, 2031

(8 years from now)

Drugs and Companies using PALIPERIDONE PALMITATE ingredient

Treatment: Treatment of schizophrenia; treatment of schizoaffective disorder as a monotherapy and as an adjunct to mood stabilizers or antidepressants; dosing regimen for the treatment of schizoaffective disorder in adults as a monotherapy and as an adjunct to mood stabilizers or antidepressants by administering two loading doses of paliperidone palmitate followed by maintenance dose(s); dosing regimen for the treatment of schizophrenia in adults by administering two loading doses of paliperidone palmitate followed by maintenance dose(s)

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage
Strength Dosage Availability
39MG/0.25ML (39MG/0.25ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
78MG/0.5ML (78MG/0.5ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
117MG/0.75ML (117MG/0.75ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
156MG/ML (156MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
234MG/1.5ML (156MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription

3. Drug name - INVOKAMET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7943788 JANSSEN PHARMS Glucopyranoside compound
Jul, 2027

(4 years from now)

US8513202 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Dec, 2027

(5 years from now)

US7943582 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Feb, 2029

(6 years from now)

CN1829728A JANSSEN PHARMS Novel Compounds
Oct, 2011

(10 years ago)

CN101111492B JANSSEN PHARMS Indole Derivatives
Mar, 2017

(5 years ago)

CN101111492A JANSSEN PHARMS Indol Derivative
Mar, 2017

(5 years ago)

CN103214471B JANSSEN PHARMS Preparation Method Of Compound With Sodium-Dependent Glucose Transporter Inhibitory Activity
Jul, 2024

(1 year, 9 months from now)

CN103214471A JANSSEN PHARMS Novel Compounds
Jul, 2024

(1 year, 9 months from now)

CN101573368B JANSSEN PHARMS Crystalline 1 - ([Beta] - D-Glucopyranosyl) - 4-Methyl-3 - [5 - (4-Fluorophenyl) - 2-Thienyl] Benzene Hemihydrate
Dec, 2027

(5 years from now)

CN101573368A JANSSEN PHARMS A Novel Crystalline Form Of 1-(Beta-D-Glucopyranosyl)-4-Methyl-3-[5-(4-Fluorophenyl)-2-Thienylmethyl]Benzene Hemihydrate With Favourable Characteristics Has Its X-Ray Powder Diffraction Pattern And/Or By Its Infrared Spectrum.
Dec, 2027

(5 years from now)

IN200600734P4 JANSSEN PHARMS Glucopyranoside Compound
Jul, 2024

(1 year, 9 months from now)

IN232231B JANSSEN PHARMS 1-(-D-Glucopyranosyl)-3-(2-Thienylmethyl)Benzene Derivatives
Jul, 2024

(1 year, 9 months from now)

IN200903871P4 JANSSEN PHARMS Crystalline Form Of 1-(B-D-Glucopyranosyl)-4-Methyl-3-[5-(4-Fluorophenyl)-2-Thienylmethyl] Benzene Hemihydrate
Dec, 2027

(5 years from now)

IN286412B JANSSEN PHARMS Crystalline Form Of 1-(B-Dglucopyranosyl)- 4-Methyl-3-[5-(4- Fluorophenyl)-2- Thienylmethyl] Benzene Hemihydrate
Dec, 2027

(5 years from now)

EP2896397B2 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter
Jul, 2024

(1 year, 9 months from now)

EP3251679A1 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter
Jul, 2024

(1 year, 9 months from now)

EP2514756B1 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter
Jul, 2024

(1 year, 9 months from now)

EP3251679B1 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter
Jul, 2024

(1 year, 9 months from now)

EP1654269B1 JANSSEN PHARMS Novel Compounds
Jul, 2024

(1 year, 9 months from now)

EP2514756A1 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter
Jul, 2024

(1 year, 9 months from now)

EP1654269A1 JANSSEN PHARMS Novel Compounds
Jul, 2024

(1 year, 9 months from now)

EP2896397B1 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter
Jul, 2024

(1 year, 9 months from now)

EP2896397A1 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter
Jul, 2024

(1 year, 9 months from now)

EP2102224B1 JANSSEN PHARMS Crystalline Form Of 1- (ß-D-Glucopyranosyl) -4 -Methyl- 3- [5- (4 -Fluorophenyl) -2-Thienylmethyl]Benzene Hemihydrate
Dec, 2027

(5 years from now)

EP2102224A1 JANSSEN PHARMS Crystalline Form Of 1- (ß-D-Glucopyranosyl) -4 -Methyl- 3- [5- (4 -Fluorophenyl) -2-Thienylmethyl]Benzene Hemihydrate
Dec, 2027

(5 years from now)

EP2102224B2 JANSSEN PHARMS Crystalline Form Of 1- (ß-D-Glucopyranosyl) -4 -Methyl- 3- [5- (4 -Fluorophenyl) -2-Thienylmethyl]Benzene Hemihydrate
Dec, 2027

(5 years from now)

EP1651658B2 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Transporter
Nov, 2028

(6 years from now)

EP1651658A1 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Transporter
Nov, 2028

(6 years from now)

EP1651658B1 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Transporter
Nov, 2028

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8785403 JANSSEN PHARMS Glucopyranoside compound Jul, 2024

(1 year, 9 months from now)

US8222219 JANSSEN PHARMS Glucopyranoside compound Apr, 2025

(2 years from now)

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; treatment of type 2 diabetes mellitus; reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
50MG;500MG TABLET;ORAL Prescription
50MG;1GM TABLET;ORAL Prescription
150MG;500MG TABLET;ORAL Prescription
150MG;1GM TABLET;ORAL Prescription

4. Drug name - INVOKAMET XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7943788 JANSSEN PHARMS Glucopyranoside compound
Jul, 2027

(4 years from now)

US8513202 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Dec, 2027

(5 years from now)

US7943582 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Feb, 2029

(6 years from now)

CN1829728A JANSSEN PHARMS Novel Compounds
Oct, 2011

(10 years ago)

CN101111492B JANSSEN PHARMS Indole Derivatives
Mar, 2017

(5 years ago)

CN101111492A JANSSEN PHARMS Indol Derivative
Mar, 2017

(5 years ago)

CN103214471B JANSSEN PHARMS Preparation Method Of Compound With Sodium-Dependent Glucose Transporter Inhibitory Activity
Jul, 2024

(1 year, 9 months from now)

CN103214471A JANSSEN PHARMS Novel Compounds
Jul, 2024

(1 year, 9 months from now)

CN101573368B JANSSEN PHARMS Crystalline 1 - ([Beta] - D-Glucopyranosyl) - 4-Methyl-3 - [5 - (4-Fluorophenyl) - 2-Thienyl] Benzene Hemihydrate
Dec, 2027

(5 years from now)

CN101573368A JANSSEN PHARMS A Novel Crystalline Form Of 1-(Beta-D-Glucopyranosyl)-4-Methyl-3-[5-(4-Fluorophenyl)-2-Thienylmethyl]Benzene Hemihydrate With Favourable Characteristics Has Its X-Ray Powder Diffraction Pattern And/Or By Its Infrared Spectrum.
Dec, 2027

(5 years from now)

IN200600734P4 JANSSEN PHARMS Glucopyranoside Compound
Jul, 2024

(1 year, 9 months from now)

IN232231B JANSSEN PHARMS 1-(-D-Glucopyranosyl)-3-(2-Thienylmethyl)Benzene Derivatives
Jul, 2024

(1 year, 9 months from now)

IN200903871P4 JANSSEN PHARMS Crystalline Form Of 1-(B-D-Glucopyranosyl)-4-Methyl-3-[5-(4-Fluorophenyl)-2-Thienylmethyl] Benzene Hemihydrate
Dec, 2027

(5 years from now)

IN286412B JANSSEN PHARMS Crystalline Form Of 1-(B-Dglucopyranosyl)- 4-Methyl-3-[5-(4- Fluorophenyl)-2- Thienylmethyl] Benzene Hemihydrate
Dec, 2027

(5 years from now)

EP2896397B2 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter
Jul, 2024

(1 year, 9 months from now)

EP3251679A1 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter
Jul, 2024

(1 year, 9 months from now)

EP2514756B1 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter
Jul, 2024

(1 year, 9 months from now)

EP3251679B1 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter
Jul, 2024

(1 year, 9 months from now)

EP1654269B1 JANSSEN PHARMS Novel Compounds
Jul, 2024

(1 year, 9 months from now)

EP2514756A1 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter
Jul, 2024

(1 year, 9 months from now)

EP1654269A1 JANSSEN PHARMS Novel Compounds
Jul, 2024

(1 year, 9 months from now)

EP2896397B1 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter
Jul, 2024

(1 year, 9 months from now)

EP2896397A1 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter
Jul, 2024

(1 year, 9 months from now)

EP2102224B1 JANSSEN PHARMS Crystalline Form Of 1- (ß-D-Glucopyranosyl) -4 -Methyl- 3- [5- (4 -Fluorophenyl) -2-Thienylmethyl]Benzene Hemihydrate
Dec, 2027

(5 years from now)

EP2102224A1 JANSSEN PHARMS Crystalline Form Of 1- (ß-D-Glucopyranosyl) -4 -Methyl- 3- [5- (4 -Fluorophenyl) -2-Thienylmethyl]Benzene Hemihydrate
Dec, 2027

(5 years from now)

EP2102224B2 JANSSEN PHARMS Crystalline Form Of 1- (ß-D-Glucopyranosyl) -4 -Methyl- 3- [5- (4 -Fluorophenyl) -2-Thienylmethyl]Benzene Hemihydrate
Dec, 2027

(5 years from now)

EP1651658B2 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Transporter
Nov, 2028

(6 years from now)

EP1651658A1 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Transporter
Nov, 2028

(6 years from now)

EP1651658B1 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Transporter
Nov, 2028

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8785403 JANSSEN PHARMS Glucopyranoside compound Jul, 2024

(1 year, 9 months from now)

US8222219 JANSSEN PHARMS Glucopyranoside compound Apr, 2025

(2 years from now)

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; treatment of type 2 diabetes mellitus; reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
50MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
50MG;500MG TABLET, EXTENDED RELEASE;ORAL Prescription
150MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
150MG;500MG TABLET, EXTENDED RELEASE;ORAL Prescription

5. Drug name - INVOKANA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7943788 JANSSEN PHARMS Glucopyranoside compound
Jul, 2027

(4 years from now)

US8513202 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Dec, 2027

(5 years from now)

US7943582 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Feb, 2029

(6 years from now)

CN1829728A JANSSEN PHARMS Novel Compounds
Oct, 2011

(10 years ago)

CN101111492B JANSSEN PHARMS Indole Derivatives
Mar, 2017

(5 years ago)

CN101111492A JANSSEN PHARMS Indol Derivative
Mar, 2017

(5 years ago)

CN103214471B JANSSEN PHARMS Preparation Method Of Compound With Sodium-Dependent Glucose Transporter Inhibitory Activity
Jul, 2024

(1 year, 9 months from now)

CN103214471A JANSSEN PHARMS Novel Compounds
Jul, 2024

(1 year, 9 months from now)

CN101573368B JANSSEN PHARMS Crystalline 1 - ([Beta] - D-Glucopyranosyl) - 4-Methyl-3 - [5 - (4-Fluorophenyl) - 2-Thienyl] Benzene Hemihydrate
Dec, 2027

(5 years from now)

CN101573368A JANSSEN PHARMS A Novel Crystalline Form Of 1-(Beta-D-Glucopyranosyl)-4-Methyl-3-[5-(4-Fluorophenyl)-2-Thienylmethyl]Benzene Hemihydrate With Favourable Characteristics Has Its X-Ray Powder Diffraction Pattern And/Or By Its Infrared Spectrum.
Dec, 2027

(5 years from now)

IN200600734P4 JANSSEN PHARMS Glucopyranoside Compound
Jul, 2024

(1 year, 9 months from now)

IN232231B JANSSEN PHARMS 1-(-D-Glucopyranosyl)-3-(2-Thienylmethyl)Benzene Derivatives
Jul, 2024

(1 year, 9 months from now)

IN200903871P4 JANSSEN PHARMS Crystalline Form Of 1-(B-D-Glucopyranosyl)-4-Methyl-3-[5-(4-Fluorophenyl)-2-Thienylmethyl] Benzene Hemihydrate
Dec, 2027

(5 years from now)

IN286412B JANSSEN PHARMS Crystalline Form Of 1-(B-Dglucopyranosyl)- 4-Methyl-3-[5-(4- Fluorophenyl)-2- Thienylmethyl] Benzene Hemihydrate
Dec, 2027

(5 years from now)

EP2896397B2 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter
Jul, 2024

(1 year, 9 months from now)

EP3251679A1 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter
Jul, 2024

(1 year, 9 months from now)

EP2514756B1 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter
Jul, 2024

(1 year, 9 months from now)

EP3251679B1 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter
Jul, 2024

(1 year, 9 months from now)

EP1654269B1 JANSSEN PHARMS Novel Compounds
Jul, 2024

(1 year, 9 months from now)

EP2514756A1 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter
Jul, 2024

(1 year, 9 months from now)

EP1654269A1 JANSSEN PHARMS Novel Compounds
Jul, 2024

(1 year, 9 months from now)

EP2896397B1 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter
Jul, 2024

(1 year, 9 months from now)

EP2896397A1 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter
Jul, 2024

(1 year, 9 months from now)

EP2102224B1 JANSSEN PHARMS Crystalline Form Of 1- (ß-D-Glucopyranosyl) -4 -Methyl- 3- [5- (4 -Fluorophenyl) -2-Thienylmethyl]Benzene Hemihydrate
Dec, 2027

(5 years from now)

EP2102224A1 JANSSEN PHARMS Crystalline Form Of 1- (ß-D-Glucopyranosyl) -4 -Methyl- 3- [5- (4 -Fluorophenyl) -2-Thienylmethyl]Benzene Hemihydrate
Dec, 2027

(5 years from now)

EP2102224B2 JANSSEN PHARMS Crystalline Form Of 1- (ß-D-Glucopyranosyl) -4 -Methyl- 3- [5- (4 -Fluorophenyl) -2-Thienylmethyl]Benzene Hemihydrate
Dec, 2027

(5 years from now)

EP1651658B2 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Transporter
Nov, 2028

(6 years from now)

EP1651658A1 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Transporter
Nov, 2028

(6 years from now)

EP1651658B1 JANSSEN PHARMS Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Transporter
Nov, 2028

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222219 JANSSEN PHARMS Glucopyranoside compound Apr, 2025

(2 years from now)

US10617668 JANSSEN PHARMS Pharmaceutical formulations May, 2031

(8 years from now)

Drugs and Companies using CANAGLIFLOZIN ingredient

Treatment: Treatment of type 2 diabetes mellitus; reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients; Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients with 100 mg canagliflozin per day; reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients with 300 mg canagliflozin per day; treatment of type 2 diabetes mellitus with 300 mg canagliflozin per day; reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients; reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients with 300 mg canagliflozin per day; reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients with 100 mg canagliflozin per day; reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; treatment of type 2 diabetes mellitus with 100 mg canagliflozin per day; treatment of type 2 diabetes mellitus

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
100MG TABLET;ORAL Prescription
300MG TABLET;ORAL Prescription

6. Drug name - PONVORY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE43728 JANSSEN PHARMS Thiazolidin-4-one derivatives
Nov, 2024

(2 years from now)

US9062014 JANSSEN PHARMS Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one
May, 2032

(9 years from now)

CN100567275C JANSSEN PHARMS As Immunosuppressive Agents 5 - (Phenyl - (Z) - Ylidene)--4 - Ketone Derivative
Nov, 2023

(1 year, 1 month from now)

CN1882555A JANSSEN PHARMS As Immunosuppressant 5 - (Phenyl - (Z) - Subyl) - Thiazole - -4 - Ketone Derivative
Nov, 2023

(1 year, 1 month from now)

CN102177144A JANSSEN PHARMS Crystalline Forms Of (R)-5-[3-Chloro-4-(2,3-Dihydroxy-Propoxy)-Benz[Z]Ylidene] -2- ([Z]-Propylimino) -3-O-Tolyl-Thiazolidin-4-One
Oct, 2029

(7 years from now)

CN102177144B JANSSEN PHARMS (R)-5-[3-Chloro--4-(2, 3-Dihydroxy-Propoxy)-Benzo [Z] Subunit]-2-([Z]-Propyl)--3-O-Tolyl--4-Ketone Of Crystal Form
Oct, 2029

(7 years from now)

IN254201B JANSSEN PHARMS Novel Thiazolidin-4-One Derivatives
Nov, 2024

(2 years from now)

IN200602225P4 JANSSEN PHARMS Novel Thiazoldin-4-One Derivatives
Nov, 2024

(2 years from now)

EP1689726A1 JANSSEN PHARMS 5-(Benz- (Z) -Ylidene) -Thiazolidin-4-One Derivatives As Immunosuppressant Agents
Nov, 2024

(2 years from now)

EP1689726B1 JANSSEN PHARMS 5-(Benz- (Z) -Ylidene) -Thiazolidin-4-One Derivatives As Immunosuppressant Agents
Nov, 2024

(2 years from now)

EP2344465B1 JANSSEN PHARMS Crystalline Forms Of (R) -5- [3-Chloro-4-( 2, 3-Dihydroxy-Propoxy)-Benz [Z]Ylidene]-2- [Z]-Propylimino) -3-O-Tolyl-Thiazolidin-4-One
Oct, 2029

(7 years from now)

EP2344465A1 JANSSEN PHARMS Crystalline Forms Of (R) -5- [3-Chloro-4-( 2, 3-Dihydroxy-Propoxy)-Benz [Z]Ylidene]-2- [Z]-Propylimino) -3-O-Tolyl-Thiazolidin-4-One
Oct, 2029

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9000018 JANSSEN PHARMS Thiazolidin-4-one-derivatives Nov, 2024

(2 years from now)

US8273779 JANSSEN PHARMS Thiazolidin 4-one derivatives Dec, 2025

(3 years from now)

US10220023 JANSSEN PHARMS Dosing regimen for a selective S1P1 receptor agonist Dec, 2035

(13 years from now)

Drugs and Companies using PONESIMOD ingredient

Treatment: Reduction of circulating lymphocytes in treating relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults; Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults; Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults using a dose titration schedule followed by a maintenance dose

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2MG TABLET;ORAL Prescription
3MG TABLET;ORAL Prescription
4MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription
6MG TABLET;ORAL Prescription
7MG TABLET;ORAL Prescription
8MG TABLET;ORAL Prescription
9MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription

7. Drug name - SPRAVATO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9592207 JANSSEN PHARMS Intranasal administration of ketamine to treat depression Mar, 2027

(4 years from now)

US8785500 JANSSEN PHARMS Intranasal administration of ketamine to treat depression Jul, 2031

(8 years from now)

US10869844 JANSSEN PHARMS Methods for the treatment of depression Sep, 2035

(12 years from now)

US11173134 JANSSEN PHARMS Methods for the treatment of depression Sep, 2035

(12 years from now)

Drugs and Companies using ESKETAMINE HYDROCHLORIDE ingredient

Treatment: Treatment of treatment-resistant depression in adult in conjunction with an oral antidepressant; Treatment of depressive symptoms in adults with mdd with acute suicidal ideation or behavior by nasally administering 56mg or 84 mg of esketamine 2x weekly for 4 weeks in conjunction with an oral antidepressant; treatment of trd in adults by nasally administering 56mg or 84mg of esketamine 2x weekly for 4 weeks during the induction phase in conjunction with an oral antidepressent; treatment of trd in adults by nasally administering 56mg or 84mg of esketamine 2x weekly for 4 weeks during the induction phase followed by a maintenance phase of 56mg or 84 mg weekly or 1x every two weeks in conjunction with an oral antidepressant; Treatment of trd in conjunction with an oral antidepressant by nasally administering 56mg or 84mg of esketamine in a maintenance phase weekly or 1x every two weeks to adults who have been administered esketamine in a induction phase for about 4 weeks

Dosage: SPRAY;NASAL

More Information on Dosage
Strength Dosage Availability
EQ 28MG BASE SPRAY;NASAL Prescription

8. Drug name - XARELTO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7157456 JANSSEN PHARMS Substituted oxazolidinones and their use in the field of blood coagulation
Aug, 2024

(1 year, 10 months from now)

CN1900074A JANSSEN PHARMS Substituted Oxazolidinones And Their Use In The Field Of Blood Coagulation
Dec, 2020

(1 year, 9 months ago)

CN1434822A JANSSEN PHARMS Substituted Oxazolidinones And Their Use In The Field Of Blood Coagulation
Dec, 2020

(1 year, 9 months ago)

CN1262551C JANSSEN PHARMS Substituted Oxazolidinones And Their Use In The Field Of Blood Coagulation
Dec, 2020

(1 year, 9 months ago)

CN1900074B JANSSEN PHARMS Substituted Oxazolidinones And Their Use In The Field Of Blood Coagulation
Dec, 2020

(1 year, 9 months ago)

CN1772751A JANSSEN PHARMS Substituted Oxazolidinones And Their Use In The Field Of Blood Coagulation
Dec, 2020

(1 year, 9 months ago)

CN100549008C JANSSEN PHARMS Substituted Oxazole Alkyl Ketone And Application Thereof In The Field Of Blood Coagulation
Dec, 2020

(1 year, 9 months ago)

IN200200763P3 JANSSEN PHARMS Oxazolidinones And Their Use
Dec, 2020

(1 year, 9 months ago)

IN211300B JANSSEN PHARMS Oxazolidinones And Their Use
Dec, 2020

(1 year, 9 months ago)

EP1526132B1 JANSSEN PHARMS Substituted Oxazolidinone Derivatives And Their Use As Factor Xa Inhibitors
Dec, 2020

(1 year, 9 months ago)

EP1526132A3 JANSSEN PHARMS Substituted Oxazolidinone Derivatives And Their Use As Factor Xa Inhibitors
Dec, 2020

(1 year, 9 months ago)

EP1526132A2 JANSSEN PHARMS Substituted Oxazolidinone Derivatives And Their Use As Factor Xa Inhibitors
Dec, 2020

(1 year, 9 months ago)

EP1261606A1 JANSSEN PHARMS Substituted Oxazolidinones And Their Use In The Field Of Blood Coagulation
Sep, 2023

(11 months from now)

EP1261606B1 JANSSEN PHARMS Substituted Oxazolidinones And Their Use In The Field Of Blood Coagulation
Sep, 2023

(11 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9415053 JANSSEN PHARMS Solid, orally administrable pharmaceutical composition Nov, 2024

(2 years from now)

US7157456

(Pediatric)

JANSSEN PHARMS Substituted oxazolidinones and their use in the field of blood coagulation Feb, 2025

(2 years from now)

US9415053

(Pediatric)

JANSSEN PHARMS Solid, orally administrable pharmaceutical composition May, 2025

(2 years from now)

US9539218 JANSSEN PHARMS Prevention and treatment of thromboembolic disorders Feb, 2034

(11 years from now)

US9539218

(Pediatric)

JANSSEN PHARMS Prevention and treatment of thromboembolic disorders Aug, 2034

(11 years from now)

US10828310 JANSSEN PHARMS Reducing the risk of cardiovascular events Jan, 2039

(16 years from now)

US10828310

(Pediatric)

JANSSEN PHARMS Reducing the risk of cardiovascular events Jul, 2039

(16 years from now)

Drugs and Companies using RIVAROXABAN ingredient

Treatment: Reducing the risk of stroke and systemic embolism; treatment of pulmonary embolism (pe); treatment of deep vein thrombosis (dvt); reduction of risk of major cardiovascular events (cv death, mi, and stroke) in chronic cad or pad; prophylaxis of venous thromboembolism in acutely ill medical patients at risk for thromboembolic complications not at high risk of bleeding; prophylaxis of thromboembolic diseases in pediatric patients aged 2 years and older with congenital heart disease who have undergone the fontan procedure and a body weight of >=50 kg; treatment of venous thromboembolism (vte) and the reduction in the risk of recurrent vte in pediatric patients from birth to less than 18 years with a body weight of 30 kg to 49.9 kg after at least 5 days of initial parenteral anticoagulant treatment; reduction in the risk of recurrence of deep vein thrombosis (dvt) and/or pulmonary embolism (pe) in patients at continued risk for recurrent dvt and/or after completion of initial treatment lasting at least 6 months; prophylaxis of deep vein thrombosis (dvt); reduction of risk of major cardiovascular events (cardiovascular death, myocardial infarction and stroke) in patients with cad; reduction of risk of major thrombotic vascular events (myocardial infarction, ischemic stroke, acute limb ischemia, and major amputation of vascular etiology) in patients with pad; treatment of venous thromboembolism (vte) and the reduction in the risk of recurrent vte in pediatric patients from birth to less than 18 years with a body weight of >=50 kg after at least 5 days of initial parenteral anticoagulant treatment; Treatment of pulmonary embolism with once daily, rapid-release tablet administered for at least five consecutive days; treatment of deep vein thrombosis with once daily, rapid-release tablet administered for at least five consecutive days; prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism in patients undergoing knee or hip replacement surgery, with once daily, rapid-release tablet administered for at least five consecutive days; reduce the risk of stroke in patients with nonvalvular atrial fibrillation with once daily, rapid-release tablet administered for at least five consecutive days; prophylaxis of venous thromboembolism in acutely ill medical patients at risk for thromboembolic complications not at high risk of bleeding with once daily, rapid-release tablet administered for at least 5 consecutive days; treatment of dvt and/or pe and reduction in the risk of recurrent dvt and/or pe in pediatric patients (>=50 kg) once daily with rapid-release tablet administered for at least 5 consecutive days after at least 5 days parenteral anticoagulant treatment; after completion of initial treatment lasting at least 6 months, to reduce the risk of recurrence of deep vein thrombosis and/or pulmonary embolism in certain patients with once daily, rapid-release tablet administered for at least 5 consecutive days; prophylaxis of pe, dvt and/or stroke in pediatric patients (>=50 kg) aged 2 years and older with congenital heart disease after fontan procedure with once daily, rapid-release tablet administered for at least 5 consecutive days; treatment of dvt and/or pe and reduction in risk of recurrent dvt and/or pe in pediatric patients (30-49.9 kg) once daily with rapid-release tablet administered for at least 5 consecutive days after at least 5 days parenteral anticoagulant treatment; Reduction of risk of cardiovascular death, myocardial infarction, and stroke in patients with cad by administering clinically proven effective amounts that are 2.5 mg rivaroxaban twice daily and 75-100 mg aspirin daily; reduction of risk of myocardial infarction and ischemic stroke in patients with pad by administering clinically proven effective amounts that are 2.5 mg rivaroxaban twice daily and 75-100 mg aspirin daily

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription
15MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.